Two Sigma Securities’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,600
| Closed | -$245K | – | 1488 |
|
|
2024
Q4 | $245K | Buy |
1,600
+100
| +7% | +$16.9K | 0.03% | 798 |
|
|
2024
Q3 | $291K | Sell |
1,500
-12,900
| -90% | -$2.7M | ﹤0.01% | 1783 |
|
|
2024
Q2 | $3.34M | Sell |
14,400
-14,800
| -51% | -$3.22M | 0.04% | 498 |
|
|
2024
Q1 | $6.3M | Buy |
29,200
+27,100
| +1,290% | +$6.35M | 0.06% | 339 |
|
|
2023
Q4 | $543K | Sell |
2,100
-4,200
| -67% | -$1.03M | 0.01% | 1496 |
|
|
2023
Q3 | $1.62M | Buy |
6,300
+3,600
| +133% | +$963K | 0.02% | 775 |
|
|
2023
Q2 | $769K | Buy |
2,700
+700
| +35% | +$208K | 0.01% | 1146 |
|
|
2023
Q1 | $556K | Buy |
+2,000
| New | +$553K | 0.01% | 1198 |
|
|
2022
Q3 | – | Sell |
-21,900
| Closed | -$4.47M | – | 2608 |
|
|
2022
Q2 | $4.47M | Buy |
21,900
+15,900
| +265% | +$3.25M | 0.16% | 144 |
|
|
2022
Q1 | $1.26M | Buy |
+6,000
| New | +$1.3M | 0.04% | 511 |
|
|
2021
Q3 | – | Sell |
-700
| Closed | -$242K | – | 1557 |
|
|
2021
Q2 | $242K | Buy |
+700
| New | +$212K | 0.01% | 1153 |
|
|
2021
Q1 | – | Sell |
-6,000
| Closed | -$1.47M | – | 904 |
|
|
2020
Q4 | $1.47M | Buy |
6,000
+4,300
| +253% | +$1.11M | 0.03% | 309 |
|
|
2020
Q3 | $482K | Sell |
1,700
-5,900
| -78% | -$1.65M | 0.01% | 613 |
|
|
2020
Q2 | $2.03M | Buy |
7,600
+6,200
| +443% | +$1.86M | 0.05% | 225 |
|
|
2020
Q1 | $443K | Sell |
1,400
-13,000
| -90% | -$3.95M | 0.01% | 667 |
|
|
2019
Q4 | $4.27M | Buy |
14,400
+4,700
| +48% | +$1.3M | 0.03% | 443 |
|
|
2019
Q3 | $2.26M | Sell |
9,700
-7,900
| -45% | -$1.84M | 0.02% | 552 |
|
|
2019
Q2 | $4.12M | Buy |
17,600
+12,600
| +252% | +$2.91M | 0.04% | 273 |
|
|
2019
Q1 | $1.18M | Sell |
5,000
-14,900
| -75% | -$4.69M | 0.01% | 500 |
|
|
2018
Q4 | $5.99M | Sell |
19,900
-20,300
| -50% | -$6.48M | 0.07% | 142 |
|
|
2018
Q3 | $14.2M | Sell |
40,200
-13,000
| -24% | -$4.48M | 0.09% | 144 |
|
|
2018
Q2 | $15.4M | Sell |
53,200
-14,900
| -22% | -$4.19M | 0.08% | 191 |
|
|
2018
Q1 | $18.6M | Buy |
68,100
+63,300
| +1,319% | +$19.6M | 0.1% | 166 |
|
|
2017
Q4 | $1.53M | Buy |
+4,800
| New | +$1.54M | 0.04% | 322 |
|
Other funds holding BIIB
Two Sigma Securities's BIIB Position: Q2 2026 in Review
Two Sigma Securities sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,335 shares — an estimated $245K sold.
Two Sigma Securities first reported a position in BIIB in Q4 2015 and held it in 23 quarters. The position peaked at $2.49M in Q3 2018. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Two Sigma Securities reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
- Two Sigma Securities sold 1,335 Biogen shares in Q2 2026, an estimated $245K.
- Two Sigma Securities first reported a position in Biogen in Q4 2015 and held it in 23 quarters.
- Two Sigma Securities's Biogen position peaked at $2.49M in Q3 2018.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.